iguratimod has been researched along with methotrexate in 32 studies
| Studies (iguratimod) | Trials (iguratimod) | Recent Studies (post-2010) (iguratimod) | Studies (methotrexate) | Trials (methotrexate) | Recent Studies (post-2010) (methotrexate) |
|---|---|---|---|---|---|
| 134 | 19 | 109 | 41,593 | 5,666 | 11,969 |
| Protein | Taxonomy | iguratimod (IC50) | methotrexate (IC50) |
|---|---|---|---|
| Thymidylate synthase | Escherichia coli | 1.8 | |
| nuclear receptor coactivator 3 isoform a | Homo sapiens (human) | 0.211 | |
| Toll-like receptor 4 | Homo sapiens (human) | 1.04 | |
| Fatty-acid amide hydrolase 1 | Mus musculus (house mouse) | 0.08 | |
| Dihydrofolate reductase | Homo sapiens (human) | 0.0522 | |
| Dihydrofolate reductase | Mus musculus (house mouse) | 0.0331 | |
| Dihydrofolate reductase | Bos taurus (cattle) | 0.0348 | |
| Dihydrofolate reductase | Gallus gallus (chicken) | 0.0545 | |
| Dihydrofolate reductase | Enterococcus faecium | 0.0014 | |
| Dihydrofolate reductase | Lacticaseibacillus casei | 0.0138 | |
| Thymidylate synthase | Homo sapiens (human) | 0.343 | |
| 5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | 0.0147 | |
| Thymidylate synthase | Escherichia coli K-12 | 0.0181 | |
| Dihydrofolate reductase | Escherichia coli K-12 | 0.1529 | |
| Bifunctional dihydrofolate reductase-thymidylate synthase | Plasmodium falciparum K1 | 0.084 | |
| Folate receptor beta | Homo sapiens (human) | 0.1585 | |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | 0.0011 | |
| Cytochrome P450 11B1, mitochondrial | Bos taurus (cattle) | 0.0012 | |
| Folate receptor alpha | Homo sapiens (human) | 0.2263 | |
| Dihydrofolate reductase | Pneumocystis carinii | 0.0717 | |
| Histidine decarboxylase | Rattus norvegicus (Norway rat) | 0.0014 | |
| Trifunctional purine biosynthetic protein adenosine-3 | Homo sapiens (human) | 0.01 | |
| Bifunctional purine biosynthesis protein ATIC | Homo sapiens (human) | 0.01 | |
| Delta-type opioid receptor | Rattus norvegicus (Norway rat) | 0.003 | |
| Mu-type opioid receptor | Rattus norvegicus (Norway rat) | 0.003 | |
| Kappa-type opioid receptor | Rattus norvegicus (Norway rat) | 0.003 | |
| Reduced folate transporter | Homo sapiens (human) | 0.012 | |
| Dihydrofolate reductase | Mycobacterium tuberculosis H37Rv | 0.0174 | |
| Folylpolyglutamate synthase, mitochondrial | Homo sapiens (human) | 3.2 | |
| Bifunctional dihydrofolate reductase-thymidylate synthase | Toxoplasma gondii | 0.0547 | |
| Bifunctional dihydrofolate reductase-thymidylate synthase | Trypanosoma cruzi | 0.11 | |
| Dihydrofolate reductase | Bacillus anthracis | 0.0136 | |
| Dihydrofolate reductase | Rattus norvegicus (Norway rat) | 0.0047 | |
| Proton-coupled folate transporter | Homo sapiens (human) | 0.1207 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (9.38) | 29.6817 |
| 2010's | 15 (46.88) | 24.3611 |
| 2020's | 14 (43.75) | 2.80 |
| Authors | Studies |
|---|---|
| Kawabata, D; Mimori, T | 1 |
| Bao, CD; Chen, SL; Dai, M; Du, F; Fan, W; Fu, Q; Huang, XF; Lü, LJ; Qian, J; Shen, N; Teng, JL; Ye, P | 1 |
| Bao, CD; Chen, ZW; Dai, M; Du, F; Fan, W; Gu, JR; Han, XH; He, PG; Li, JH; Li, XF; Lu, LJ; Tao, Y; Teng, JL; Wu, HX; Xu, JH; Yang, NP; Yu, H; Zhang, MJ; Zhao, YH | 1 |
| Hara, M; Ishiguro, N; Katayama, K; Kondo, M; Mimori, T; Nagai, K; Soen, S; Sumida, T; Yamaguchi, T; Yamamoto, K | 2 |
| Mucke, HA | 1 |
| Gu, Y; Jin, B; Liu, W; Luo, Q; Qian, C; Shen, Y; Sun, Y; Tao, F; Wu, X; Xu, Q | 1 |
| Kobayashi, T; Okamura, K; Okura, C; Takagishi, K; Yonemoto, Y | 1 |
| Hara, M; Tanaka, K; Yamaguchi, T | 1 |
| Duan, XW; Mao, SY; Shang, JJ; Shi, XD; Zhang, XL | 1 |
| Asai, N; Asai, S; Funahashi, K; Hirano, Y; Ishiguro, N; Ito, T; Kanayama, Y; Kanda, H; Kaneko, A; Kato, T; Kojima, T; Saito, K; Takagi, H; Takahashi, N; Takemoto, T; Terabe, K; Yoshioka, Y | 1 |
| Hou, N; Li, X; Liu, H; Lyu, J; Song, L; Xia, Z | 1 |
| Arita, Y; Kobayashi, M; Ohsone, Y; Okano, Y; Taguchi, H; Tono, T | 1 |
| Bi, LQ; Ding, R; Li, P; Wang, XT; Xu, TS; Zhang, X | 1 |
| Bi, L; Li, P; Ma, C; Wang, X; Zhao, F | 1 |
| Guo, C; Wu, R; Zheng, N | 1 |
| Hagihara, M; Hua, J; Ide, S; Inoue, M; Mese, T; Ohara, S | 1 |
| Ayabe, K; Chikuda, H; Kaneko, T; Okamura, K; Sakane, H; Suto, T; Takeuchi, K; Tamura, Y; Yonemoto, Y | 1 |
| Ikeuchi, S; Ishiguro, N; Ishii, M; Shibata, K; Yoshimura, A | 1 |
| Bian, W; Chen, D; Chen, J; Fu, J; Li, Y; Li, Z; Liu, Y; Sun, X; Zhang, W; Zhang, Y; Zhao, X | 1 |
| Shrestha, S; Yang, C; Zhang, J; Zhao, J | 2 |
| Kodera, H; Mizutani, S; Nanki, T; Sato, Y; Yasuoka, H; Yoshida, S | 1 |
| Chen, LJ; Li, JY; Tian, F; Wen, ZH; Zhou, YJ | 1 |
| Hata, K; Kotani, T; Matsuda, S; Matsumura, Y; Takeuchi, T; Yoshikawa, A | 1 |
| Fujimoto-Hirakawa, Y; Fukuda, W; Iwai, T; Kobayashi, T; Kuriyama, K; Kuroda, J; Matsumoto, Y; Mizutani, S; Nagata, H; Nishikawa, R; Ohshiro, M; Shimura, Y; Tsukamoto, T; Uchiyama, H; Yamamoto-Sugitani, M | 1 |
| Ma, RR; Wu, F; Wu, TJ; Ying, ZH; Yu, JJ; Zhang, Y | 1 |
| Dan, J; Liu, Y; Tan, J | 1 |
| Fukuda, K; Funahashi, K; Hayashi, S; Itami, T; Kinoshita, K; Kuroda, R; Maeda, T; Matsubara, T; Matsumura, I; Nozaki, Y; Oribe, M; Tomita, D | 1 |
| Amuro, H; Ebina, K; Etani, Y; Hara, R; Hashimoto, M; Hirano, T; Hirao, M; Jinno, S; Katayama, M; Kotani, T; Kumanogoh, A; Maeda, Y; Murata, K; Nakata, K; Okada, S; Okita, Y; Onishi, A; Shiba, H; Son, Y; Yamamoto, K; Yamamoto, W | 1 |
| Ge, W; Shu, Q; Wang, M; Yang, N; Zhang, H; Zhang, T; Zhu, H | 1 |
| Jingzhou, Z; Xin, KQ; Xiong, Z | 1 |
6 review(s) available for iguratimod and methotrexate
| Article | Year |
|---|---|
[Disease modifying anti-rheumatic drugs (DMARDs): an overview].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Benzopyrans; Cysteine; Evidence-Based Medicine; Gold Sodium Thiomalate; Humans; Isoxazoles; Leflunomide; Meta-Analysis as Topic; Methotrexate; Randomized Controlled Trials as Topic; Sulfasalazine; Sulfonamides | 2005 |
Iguratimod: a new disease-modifying antirheumatic drug.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Chromones; Drug Therapy, Combination; Humans; Methotrexate; Sulfasalazine; Sulfonamides | 2012 |
Iguratimod for the treatment of rheumatoid arthritis in Japan.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Chromones; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Immunosuppressive Agents; Japan; Methotrexate; Sulfonamides | 2015 |
Relative efficacy and safety of iguratimod monotherapy for the treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Blood Sedimentation; C-Reactive Protein; Chromones; Humans; Methotrexate; Randomized Controlled Trials as Topic; Sulfonamides; Treatment Outcome | 2020 |
Efficacy and safety of iguratimod combined with methotrexate vs. methotrexate alone in rheumatoid arthritis : A systematic review and meta-analysis of randomized controlled trials.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; China; Chromones; Drug Therapy, Combination; Humans; Methotrexate; Randomized Controlled Trials as Topic; Sulfonamides; Treatment Outcome | 2021 |
Iguratimod combination therapy compared with methotrexate monotherapy for the treatment of rheumatoid arthritis: a systematic review and meta-analysis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Chromones; Drug Therapy, Combination; Humans; Methotrexate; Sulfonamides | 2021 |
6 trial(s) available for iguratimod and methotrexate
| Article | Year |
|---|---|
Multicenter, randomized, double-blind, controlled trial of treatment of active rheumatoid arthritis with T-614 compared with methotrexate.
Topics: Administration, Oral; Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Benzopyrans; China; Double-Blind Method; Female; Humans; Immunoglobulin A; Immunoglobulin G; Immunoglobulin M; Male; Methotrexate; Middle Aged; Sulfonamides; Treatment Outcome | 2009 |
Concomitant iguratimod therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Chromones; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Methotrexate; Middle Aged; Sulfonamides; Treatment Outcome | 2013 |
Safety and efficacy of combination therapy of iguratimod with methotrexate for patients with active rheumatoid arthritis with an inadequate response to methotrexate: an open-label extension of a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Chromones; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Methotrexate; Middle Aged; Retreatment; Sulfonamides; Treatment Outcome | 2014 |
Efficacy and safety evaluation of a combination of iguratimod and methotrexate therapy for active rheumatoid arthritis patients: a randomized controlled trial.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; C-Reactive Protein; China; Chromones; Drug Therapy, Combination; Female; Humans; Male; Methotrexate; Middle Aged; Sulfonamides; Treatment Outcome | 2015 |
Iguratimod in combination with methotrexate in active rheumatoid arthritis : Therapeutic effects.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Attitude of Health Personnel; China; Chromones; Dose-Response Relationship, Drug; Drug Combinations; Evidence-Based Medicine; Female; Humans; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Patient Satisfaction; Prevalence; Risk Factors; Sulfonamides; Treatment Outcome | 2016 |
Clinical Efficacy of Methotrexate Combined with Iguratimod on Patients with Rheumatoid Arthritis and Its Influence on the Expression Levels of HOTAIR in Serum.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Chromones; Drug Therapy, Combination; Female; Gene Expression; Humans; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; RNA, Long Noncoding; Sulfonamides; Tumor Necrosis Factor-alpha | 2021 |
20 other study(ies) available for iguratimod and methotrexate
| Article | Year |
|---|---|
T-614, a novel immunomodulator, attenuates joint inflammation and articular damage in collagen-induced arthritis.
Topics: Animals; Arthritis, Experimental; Benzopyrans; Cartilage, Articular; Drug Therapy, Combination; Female; Inflammation Mediators; Knee Joint; Methotrexate; Rats; Rats, Wistar; Sulfonamides | 2008 |
A novel disease-modifying antirheumatic drug, iguratimod, ameliorates murine arthritis by blocking IL-17 signaling, distinct from methotrexate and leflunomide.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antirheumatic Agents; Arthritis, Experimental; Arthritis, Rheumatoid; Chromones; Collagen; I-kappa B Kinase; Inflammation; Interleukin-17; Isoxazoles; Leflunomide; Male; Methotrexate; Mice; Mice, Inbred DBA; Phosphorylation; Signal Transduction; Sulfonamides; Synovial Membrane; TNF Receptor-Associated Factor 5 | 2013 |
Efficacy of the clinical use of iguratimod therapy in patients with rheumatoid arthritis.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Chromones; Drug Therapy, Combination; Female; Humans; Male; Matrix Metalloproteinase 3; Methotrexate; Middle Aged; Severity of Illness Index; Sulfonamides; Treatment Outcome | 2015 |
Disease activity early in treatment as a predictor of future low disease activity in RA patients treated with iguratimod.
Topics: Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Sedimentation; Chromones; Drug Therapy, Combination; Female; Humans; Male; Methotrexate; Middle Aged; Predictive Value of Tests; Registries; Remission Induction; Retrospective Studies; Severity of Illness Index; Sulfonamides; Treatment Outcome | 2016 |
Pneumocystis jirovecii pneumonia developed in a patient with rheumatoid arthritis after 14 weeks of iguratimod add-on to treatment with methotrexate and etanercept.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Chromones; Drug Therapy, Combination; Etanercept; Female; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Long Term Adverse Effects; Methotrexate; Pneumocystis carinii; Pneumonia, Pneumocystis; Sulfonamides | 2018 |
Effect of iguratimod and methotrexate on RANKL and OPG expression in serum and IL-1β-induced fibroblast-like synoviocytes from patients with rheumatoid arthritis.
Topics: Adult; Arthritis, Rheumatoid; Blotting, Western; Chromones; Enzyme-Linked Immunosorbent Assay; Female; Fibroblasts; Humans; Interleukin-1beta; Male; Methotrexate; Middle Aged; Osteoprotegerin; RANK Ligand; Real-Time Polymerase Chain Reaction; RNA, Messenger; Sulfonamides; Synoviocytes | 2016 |
Effects of iguratimod on the levels of circulating regulators of bone remodeling and bone remodeling markers in patients with rheumatoid arthritis.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; Bone and Bones; Bone Remodeling; Chromones; Drug Therapy, Combination; Female; Humans; Male; Methotrexate; Middle Aged; Sulfonamides | 2017 |
Iguratimod is effective in refractory rheumatoid arthritis patients with inadequate response to methotrexate-cyclosporin A-hydroxychloroquine-prednisone.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Chromones; Cyclosporine; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Hydroxychloroquine; Male; Methotrexate; Middle Aged; Prednisone; Retrospective Studies; Sulfonamides; Treatment Outcome | 2018 |
Methotrexate-associated Intravascular Large B-cell Lymphoma in a Patient with Rheumatoid Arthritis: A Very Rare Case.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Chromones; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoproliferative Disorders; Male; Methotrexate; Neoplasm Recurrence, Local; Rare Diseases; Rituximab; Sulfonamides; Treatment Outcome | 2018 |
The three-year efficacy of iguratimod in clinical daily practice in patients with rheumatoid arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Chromones; Drug Therapy, Combination; Female; Humans; Male; Methotrexate; Middle Aged; Prednisolone; Sulfonamides | 2019 |
Investigation of the predictors of the response to Iguratimod therapy: A
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Chromones; Drug Therapy, Combination; Female; Humans; Male; Methotrexate; Middle Aged; Product Surveillance, Postmarketing; Sulfonamides | 2020 |
Efficacy and safety of iguratimod on patients with relapsed or refractory IgG4-related disease.
Topics: Adult; Aged; Chromones; Cyclophosphamide; Female; Glucocorticoids; Humans; Immunoglobulin G; Immunoglobulin G4-Related Disease; Immunosuppressive Agents; Lacrimal Apparatus; Leflunomide; Male; Methotrexate; Middle Aged; Mycophenolic Acid; Prednisone; Recurrence; Retrospective Studies; Salivary Glands; Sulfonamides; Treatment Outcome; Young Adult | 2020 |
Clinical effectiveness of iguratimod based on real-world data of patients with rheumatoid arthritis.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Chromones; Drug Therapy, Combination; Female; Humans; Male; Methotrexate; Retrospective Studies; Sulfonamides; Treatment Outcome | 2021 |
The addition of iguratimod can reduce methotrexate dose in rheumatoid arthritis with clinical remission.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Chromones; Drug Therapy, Combination; Humans; Methotrexate; Remission Induction; Sulfonamides; Treatment Outcome | 2022 |
Iguratimod triggers the relapse of methotrexate-associated lymphoproliferative disorder.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Chromones; Female; Humans; Immunosuppressive Agents; Lymphoproliferative Disorders; Methotrexate; Recurrence; Sulfonamides | 2021 |
The effects of iguratimod combined with methotrexate and hydroxychloroquine on bone mineral density in patients with rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Bone Density; Chromones; Drug Therapy, Combination; Humans; Hydroxychloroquine; Methotrexate; Retrospective Studies; Sulfonamides | 2021 |
Iguratimod versus salazosulfapyridine in rheumatoid arthritis patients with an inadequate response to methotrexate: Adjusted with propensity score matching.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Methotrexate; Propensity Score; Retrospective Studies; Sulfasalazine; Treatment Outcome | 2023 |
Add-on effectiveness of methotrexate or iguratimod in patients with rheumatoid arthritis exhibiting an inadequate response to Janus kinase inhibitors: The ANSWER cohort study.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Janus Kinase Inhibitors; Male; Methotrexate; Middle Aged; Retrospective Studies; Sulfonamides; Treatment Outcome | 2023 |
Serum proteomics analysis of biomarkers for evaluating clinical response to MTX/IGU therapy in early rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Biomarkers; Blood Proteins; Drug Therapy, Combination; Humans; Methotrexate; Proteomics; Treatment Outcome | 2023 |
Combination therapy of methotrexate and iguratimod for female patients with moderate to severe active rheumatoid arthritis and its impact on ovarian function.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Female; Humans; Methotrexate; Treatment Outcome | 2023 |